Whereas in VEXAS syndrome, UBA1 mutations alone are thought to drive both the inflammatory and MDS phenotypes, in UBA1‐wildtype patients with MDS/CMML, early somatic mutations in TET2/IDH1 (and/or SRSF2) are thought to contribute to the MDS/CMML and SIAD components [7, 8]. This evidence concerns the gene SRSF2 and VEXAS syndrome.